スルホニル尿素化合物

WordNet

create by mixing or combining
(chemistry) a substance formed by chemical union of two or more elements or ingredients in definite proportion by weight (同)chemical_compound
put or add together; "combine resources" (同)combine
an enclosure of residences and other building (especially in the Orient)
a whole formed by a union of two or more elements or parts
combine so as to form a whole; mix; "compound the ingredients" (同)combine
calculate principal and interest
composed of more than one part; "compound leaves are composed of several lobes; "compound flower heads"
consisting of two or more substances or ingredients or elements or parts; "soap is a compound substance"; "housetop is a compound word"; "a blackberry is a compound fruit"
antidiabetic consisting of any of several drugs that reduce the level of glucose in the blood; used to treat diabetes mellitus
combined into or constituting a chemical compound

PrepTutorEJDIC

(…になるように)〈要素・成分など〉'を'混ぜ合わせる《+『名』+『into』+『名』》;(…から)〈薬など〉'を'調合する,混ぜ合わせて作る《+『名』+『from』(『of』)+『名』》 / 《しばしば受動態で》〈めんどうな事・損害など〉'を'もっとひどくする / 〈利子〉'を'複利で計算する / (…と)話し合いをつける,妥協する《+『with』+『名』》 / 複合の,合成の / 『合成物』,混合物,調合物;化合物 / 複合語,合成語(classroom, heart-to-heartなどをいう)
(異民族の家屋・商館などがある)囲み地区,構内

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 糖尿病の治療におけるスルホニル尿素およびメグリチニド sulfonylureas and meglitinides in the treatment of diabetes mellitus
2. スルホニル尿素剤中毒 sulfonylurea agent poisoning
3. 透析前慢性腎臓病または末期腎不全を伴う2型糖尿病患者における高血糖のマネージメント management of hyperglycemia in patients with type 2 diabetes and pre dialysis chronic kidney disease or end stage renal disease
4. 2型糖尿病における持続性高血糖のマネージメント management of persistent hyperglycemia in type 2 diabetes mellitus
5. 高齢患者における2型糖尿病の治療 treatment of type 2 diabetes mellitus in the older patient

English Journal

The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract.

Zur M1, Cohen N1, Agbaria R1, Dahan A2.
International journal of pharmaceutics.Int J Pharm.2015 Jul 15;489(1-2):304-10. doi: 10.1016/j.ijpharm.2015.05.002. Epub 2015 May 6.
The purpose of this work was to study the challenges and prospects of regional-dependent absorption in a controlled-release scenario, through the oral biopharmaceutics of the sulfonylurea antidiabetic drug glipizide. The BCS solubility class of glipizide was determined, and its physicochemical prope
PMID 25957705

[Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].

Winkler G1.
Orvosi hetilap.Orv Hetil.2015 Mar 29;156(13):511-5. doi: 10.1556/OH.2015.30114.
in

English, HungarianA szulfanilureavegyületek hosszú ideje a 2-es típusú diabetes vércukorcsökkentő kezelésének alapgyógyszerei. Az inkretin mechanizmusú antidiabetikumok megjelenésével azonban időről időre felmerül, van-e helye továbbra is e gyógyszercsoportnak napjaink ter�

PMID 25796278

[Transition and perspectives of antidiabetic agents].

Kawanami D, Utsunomiya K.
Nihon rinsho. Japanese journal of clinical medicine.Nihon Rinsho.2015 Mar;73(3):375-81.
History of oral hypoglycemic agents (OHA) started in 1942 that was 20 years delayed to the discovery of insulin. The first two OHAs (sulfonylurea and biguanide) were discovered by chance. Ancient knowledge regarding antidiabetic agents present in nature is significant for the development of some dru
PMID 25812361